CLAIMS

1. Use of a substance that suppresses an expression or function of Syndecan-4 (SDC4) in the manufacture of a cancer stem cell elimination agent, wherein the substance that suppresses the expression of SDC4 is

(a) a nucleic acid having RNAi activity against a transcription product of SDC4 gene, or a precursor thereof,

(b) an antisense nucleic acid against a transcription product of SDC4 gene, or

(c) a ribozyme nucleic acid against a transcription product of SDC4 gene,

and wherein the substance that suppresses the function of SDC4 is

(d) an antibody against SDC4.

2. The use according to claim 1, wherein the substance that suppresses the expression of SDC4 is a nucleic acid comprising a nucleotide sequence complementary to a sequence consisting of at least 15 consecutive nucleotides in the region indicated by nucleotide numbers 41 - 637 in the nucleotide sequence shown in SEQ ID NO: 1, or a precursor thereof.

3. The use according to claim 1, wherein the substance that suppresses the expression of SDC4 is a nucleic acid comprising a nucleotide sequence complementary to a sequence consisting of at least 15 consecutive nucleotides in the region indicated by nucleotide numbers 475 - 606 in the nucleotide sequence shown in SEQ ID NO: 1, or a precursor thereof.

4. The use according to claim 2 or 3, wherein the agent is siRNA.

5. The use according to any one of claims 1 to 4, wherein the agent is used in combination with other antitumor drug.

6. The use according to claim 7, wherein said other antitumor drug is one or more kinds selected from a chemotherapy drug, a Wnt inhibitor and an mTOR inhibitor.